Report cover image

Global Long-Term Asthma Drugs Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 193 Pages
SKU # APRC20361759

Description

Summary

According to APO Research, The global Long-Term Asthma Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Long-Term Asthma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Long-Term Asthma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Long-Term Asthma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Long-Term Asthma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Long-Term Asthma Drugs include Novartis, Merck, Roche, Pfizer, GlaxoSmithKline, AstraZeneca, Vectura Group, Teva Pharmaceutical and Boehringer Ingelheim, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Long-Term Asthma Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Long-Term Asthma Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Long-Term Asthma Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-Term Asthma Drugs revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-Term Asthma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Long-Term Asthma Drugs revenue, projected growth trends, production technology, application and end-user industry.

Long-Term Asthma Drugs Segment by Company

Novartis
Merck
Roche
Pfizer
GlaxoSmithKline
AstraZeneca
Vectura Group
Teva Pharmaceutical
Boehringer Ingelheim
Long-Term Asthma Drugs Segment by Type

Tablet
Spray
Long-Term Asthma Drugs Segment by Application

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Long-Term Asthma Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-Term Asthma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-Term Asthma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-Term Asthma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Long-Term Asthma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Long-Term Asthma Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-Term Asthma Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Long-Term Asthma Drugs Market by Type
1.2.1 Global Long-Term Asthma Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Tablet
1.2.3 Spray
1.3 Long-Term Asthma Drugs Market by Application
1.3.1 Global Long-Term Asthma Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Retail Pharmacy
1.3.3 Online Pharmacy
1.3.4 Hospital Pharmacy
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Long-Term Asthma Drugs Market Dynamics
2.1 Long-Term Asthma Drugs Industry Trends
2.2 Long-Term Asthma Drugs Industry Drivers
2.3 Long-Term Asthma Drugs Industry Opportunities and Challenges
2.4 Long-Term Asthma Drugs Industry Restraints
3 Global Growth Perspective
3.1 Global Long-Term Asthma Drugs Market Perspective (2020-2031)
3.2 Global Long-Term Asthma Drugs Growth Trends by Region
3.2.1 Global Long-Term Asthma Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Long-Term Asthma Drugs Market Size by Region (2020-2025)
3.2.3 Global Long-Term Asthma Drugs Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Long-Term Asthma Drugs Revenue by Players
4.1.1 Global Long-Term Asthma Drugs Revenue by Players (2020-2025)
4.1.2 Global Long-Term Asthma Drugs Revenue Market Share by Players (2020-2025)
4.1.3 Global Long-Term Asthma Drugs Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Long-Term Asthma Drugs Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Long-Term Asthma Drugs Key Players Headquarters & Area Served
4.4 Global Long-Term Asthma Drugs Players, Product Type & Application
4.5 Global Long-Term Asthma Drugs Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Long-Term Asthma Drugs Market CR5 and HHI
4.6.3 2024 Long-Term Asthma Drugs Tier 1, Tier 2, and Tier 3
5 Long-Term Asthma Drugs Market Size by Type
5.1 Global Long-Term Asthma Drugs Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Long-Term Asthma Drugs Revenue by Type (2020-2031)
5.3 Global Long-Term Asthma Drugs Revenue Market Share by Type (2020-2031)
6 Long-Term Asthma Drugs Market Size by Application
6.1 Global Long-Term Asthma Drugs Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Long-Term Asthma Drugs Revenue by Application (2020-2031)
6.3 Global Long-Term Asthma Drugs Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Comapny Information
7.1.2 Novartis Business Overview
7.1.3 Novartis Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.1.4 Novartis Long-Term Asthma Drugs Product Portfolio
7.1.5 Novartis Recent Developments
7.2 Merck
7.2.1 Merck Comapny Information
7.2.2 Merck Business Overview
7.2.3 Merck Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.2.4 Merck Long-Term Asthma Drugs Product Portfolio
7.2.5 Merck Recent Developments
7.3 Roche
7.3.1 Roche Comapny Information
7.3.2 Roche Business Overview
7.3.3 Roche Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.3.4 Roche Long-Term Asthma Drugs Product Portfolio
7.3.5 Roche Recent Developments
7.4 Pfizer
7.4.1 Pfizer Comapny Information
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.4.4 Pfizer Long-Term Asthma Drugs Product Portfolio
7.4.5 Pfizer Recent Developments
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Comapny Information
7.5.2 GlaxoSmithKline Business Overview
7.5.3 GlaxoSmithKline Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.5.4 GlaxoSmithKline Long-Term Asthma Drugs Product Portfolio
7.5.5 GlaxoSmithKline Recent Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Comapny Information
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.6.4 AstraZeneca Long-Term Asthma Drugs Product Portfolio
7.6.5 AstraZeneca Recent Developments
7.7 Vectura Group
7.7.1 Vectura Group Comapny Information
7.7.2 Vectura Group Business Overview
7.7.3 Vectura Group Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.7.4 Vectura Group Long-Term Asthma Drugs Product Portfolio
7.7.5 Vectura Group Recent Developments
7.8 Teva Pharmaceutical
7.8.1 Teva Pharmaceutical Comapny Information
7.8.2 Teva Pharmaceutical Business Overview
7.8.3 Teva Pharmaceutical Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.8.4 Teva Pharmaceutical Long-Term Asthma Drugs Product Portfolio
7.8.5 Teva Pharmaceutical Recent Developments
7.9 Boehringer Ingelheim
7.9.1 Boehringer Ingelheim Comapny Information
7.9.2 Boehringer Ingelheim Business Overview
7.9.3 Boehringer Ingelheim Long-Term Asthma Drugs Revenue and Gross Margin (2020-2025)
7.9.4 Boehringer Ingelheim Long-Term Asthma Drugs Product Portfolio
7.9.5 Boehringer Ingelheim Recent Developments
8 North America
8.1 North America Long-Term Asthma Drugs Revenue (2020-2031)
8.2 North America Long-Term Asthma Drugs Revenue by Type (2020-2031)
8.2.1 North America Long-Term Asthma Drugs Revenue by Type (2020-2025)
8.2.2 North America Long-Term Asthma Drugs Revenue by Type (2026-2031)
8.3 North America Long-Term Asthma Drugs Revenue Share by Type (2020-2031)
8.4 North America Long-Term Asthma Drugs Revenue by Application (2020-2031)
8.4.1 North America Long-Term Asthma Drugs Revenue by Application (2020-2025)
8.4.2 North America Long-Term Asthma Drugs Revenue by Application (2026-2031)
8.5 North America Long-Term Asthma Drugs Revenue Share by Application (2020-2031)
8.6 North America Long-Term Asthma Drugs Revenue by Country
8.6.1 North America Long-Term Asthma Drugs Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Long-Term Asthma Drugs Revenue by Country (2020-2025)
8.6.3 North America Long-Term Asthma Drugs Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Long-Term Asthma Drugs Revenue (2020-2031)
9.2 Europe Long-Term Asthma Drugs Revenue by Type (2020-2031)
9.2.1 Europe Long-Term Asthma Drugs Revenue by Type (2020-2025)
9.2.2 Europe Long-Term Asthma Drugs Revenue by Type (2026-2031)
9.3 Europe Long-Term Asthma Drugs Revenue Share by Type (2020-2031)
9.4 Europe Long-Term Asthma Drugs Revenue by Application (2020-2031)
9.4.1 Europe Long-Term Asthma Drugs Revenue by Application (2020-2025)
9.4.2 Europe Long-Term Asthma Drugs Revenue by Application (2026-2031)
9.5 Europe Long-Term Asthma Drugs Revenue Share by Application (2020-2031)
9.6 Europe Long-Term Asthma Drugs Revenue by Country
9.6.1 Europe Long-Term Asthma Drugs Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Long-Term Asthma Drugs Revenue by Country (2020-2025)
9.6.3 Europe Long-Term Asthma Drugs Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Long-Term Asthma Drugs Revenue (2020-2031)
10.2 China Long-Term Asthma Drugs Revenue by Type (2020-2031)
10.2.1 China Long-Term Asthma Drugs Revenue by Type (2020-2025)
10.2.2 China Long-Term Asthma Drugs Revenue by Type (2026-2031)
10.3 China Long-Term Asthma Drugs Revenue Share by Type (2020-2031)
10.4 China Long-Term Asthma Drugs Revenue by Application (2020-2031)
10.4.1 China Long-Term Asthma Drugs Revenue by Application (2020-2025)
10.4.2 China Long-Term Asthma Drugs Revenue by Application (2026-2031)
10.5 China Long-Term Asthma Drugs Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Long-Term Asthma Drugs Revenue (2020-2031)
11.2 Asia Long-Term Asthma Drugs Revenue by Type (2020-2031)
11.2.1 Asia Long-Term Asthma Drugs Revenue by Type (2020-2025)
11.2.2 Asia Long-Term Asthma Drugs Revenue by Type (2026-2031)
11.3 Asia Long-Term Asthma Drugs Revenue Share by Type (2020-2031)
11.4 Asia Long-Term Asthma Drugs Revenue by Application (2020-2031)
11.4.1 Asia Long-Term Asthma Drugs Revenue by Application (2020-2025)
11.4.2 Asia Long-Term Asthma Drugs Revenue by Application (2026-2031)
11.5 Asia Long-Term Asthma Drugs Revenue Share by Application (2020-2031)
11.6 Asia Long-Term Asthma Drugs Revenue by Country
11.6.1 Asia Long-Term Asthma Drugs Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Long-Term Asthma Drugs Revenue by Country (2020-2025)
11.6.3 Asia Long-Term Asthma Drugs Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Long-Term Asthma Drugs Revenue (2020-2031)
12.2 SAMEA Long-Term Asthma Drugs Revenue by Type (2020-2031)
12.2.1 SAMEA Long-Term Asthma Drugs Revenue by Type (2020-2025)
12.2.2 SAMEA Long-Term Asthma Drugs Revenue by Type (2026-2031)
12.3 SAMEA Long-Term Asthma Drugs Revenue Share by Type (2020-2031)
12.4 SAMEA Long-Term Asthma Drugs Revenue by Application (2020-2031)
12.4.1 SAMEA Long-Term Asthma Drugs Revenue by Application (2020-2025)
12.4.2 SAMEA Long-Term Asthma Drugs Revenue by Application (2026-2031)
12.5 SAMEA Long-Term Asthma Drugs Revenue Share by Application (2020-2031)
12.6 SAMEA Long-Term Asthma Drugs Revenue by Country
12.6.1 SAMEA Long-Term Asthma Drugs Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Long-Term Asthma Drugs Revenue by Country (2020-2025)
12.6.3 SAMEA Long-Term Asthma Drugs Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.